News

Providing education about patients’ diseases was difficult, according to 32% of registered nurses and 29% of infusion nurses.

Early infection incidence in patients with multiple myeloma following treatment with cilta-cel infusion highlights the necessity of toxicity monitoring.

Authors noted that BiTEs have expanded the treatment paradigms for several types of solid tumors and blood cancers; however, toxicities associated with this class of agents have raised safety concerns.

Findings highlighted that increased physical activity was associated with a variety of benefits in improving overall well-being in early adolescent and young adult survivors.

Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes.

Danielle Fournier, DNP, APRN, AGPCNP-BC, AOCNP, discusses the role of oncology nurses in genomic testing.

“When discussing treatment options with patients, it is important to consider efficacy, safety, and the impact of treatment on patients’ quality of life [QOL]…,” noted Brenda Martone, RN, APP.

Nurse practitioners should listen to patients’ concerns and be ready with questions when it comes to germline testing, according to an expert.

Tara Sweeney, BSN, RN, OCN, CHPN discussed best care for the health and well-being of a person across all stages of their cancer survivorship.

Social determinants of health like transportation and financial increased the occurrence of psychoneurological symptoms in breast cancer survivors.

In accordance with CMS quality measures, interventions like provider/patient education and better access to care help reduce ED visits after chemotherapy.

The FDA approved bevacizumab-nwgd across several gastrointestinal, gynecological, brain, and lung cancer types.

Oncology nurses and APPs can enhance patients’ comfort by counseling patients on what integrative care is and working to make those options accessible.

The subcutaneous formulation of nivolumab showed comparable efficacy and safety to the IV formulation in advanced clear cell renal cell carcinoma.

Using risk assessment and nurse education in the High ED/Admission Risk Therapy (HEART) protocol reduced ED visits by 18% after chemoradiation treatment.

The FDA approved larotrectinib for use in adult and pediatric patients with NTRK fusion-positive solid tumors with few other options.

The 2025 Extraordinary Healer® Award was presented during the 50th Annual Oncology Nursing Society Congress, recognizing oncology nursing professionals' dedication and impact.

Pacritinib showed early activity and was safe for patients with multi-refractory chronic graft-vs-host disease.

Using liquid biopsies to test for ESR1 mutations in breast cancer is more feasible for patients and has quicker turnaround times.

The accelerated approval for nivolumab monotherapy in unresectable/metastatic MSI-H/dMMR CRC has also been converted to regular approval.

VXM01 plus avelumab was tolerable and could potentially produce clinically meaningful responses in patients with recurrent glioblastoma.

Practicing at top of licensure can create opportunities for oncology APPs to engage with patients and other providers in new ways.

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell malignancies in real-world data.

Oncology nurses can enhance endometrial cancer recovery by fostering strong social support networks and improving communication with the patient.

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian cancer.

Working with patients in new contexts can provide meaning for oncology PAs, potentially reducing burnout, according to Eric Tetzlaff, MHS, PA-C, DFAAPA.

Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer.

Katherine Cohen, MSN, FNP-C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.